It blocks the interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, but may not have a significant effect on the splenic niche and structure. Here, PDCD1LG2 is linked to neoplasm.